RenalytixAI: KidneyIntelX

RenalytixAI has announced the commercial launch of its KidneyIntelX clinical testing platform, which provides risk assessment of progressive decline in kidney function or kidney failure in patients with early-stage diabetic kidney disease. KidneyIntelX applies machine-learning algorithms to assess predictive blood-based biomarkers and electronic health record data to identify progressive kidney disease in at-risk patients. 

The firm submitted a 510(k) application to the US Food and Drug Administration for the assay last month.